JWJohn Waller

John Waller

*This is an algorithmically generated author record based on publicly available information.

John Waller has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • A. Kruse

    Platelet Disorder Support Association Cleveland United States

    1 shared publication
  • Adam J. Mead

    Oxford NIHR Biomedical Research Centre, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

    1 shared publication
  • B. Lovrencic

    Italian Association Immune Thrombocytopenic Purpura Caprino Veronese Italy

    1 shared publication
  • Barbara Taylor

    Haematology Franchise, Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK

    1 shared publication
  • Caroline-Julia Kruse

    Department of Functional Sciences, Faculty of Veterinary Medicine, Physiology and Sport Medicine, Fundamental and Applied Research for Animals & Health (FARAH), University of Liège, 4000 Liège, Belgium

    1 shared publication
  • Christopher M. Black

    Outcomes Research, Merck & Co., Inc., Rahway, NJ, United States

    1 shared publication

Latest Publications

  • Open Access

    PF711 DIFFERENCES IN PERCEPTIONS ON TREATMENT APPROACHES BETWEEN PHYSICIANS AND ITP PATIENTS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I‐WISH)

    by A. Kruse, C. Kruse, M. Morgan, J. Bussel, D. Provan, W. Ghanima, M. Hou, C. Santoro, M. Michel, B. Lovrencic, et al.

    Background: Guidelines recommend that adult patients (pts) with persistent or chronic immune thrombocytopenia (ITP) who are corticosteroid (CS) dependent or unresponsive to 1st‐line CS therapy be treated with splenectomy, rituximab, or a thrombopoietin receptor agonist (TPO‐RA).Aims: I‐WISh studied the burden of ITP and its quality of life impact using a global pts and physicians (MDs) sampling frame. MDs and ITP pts beliefs, perceptions, and attitudes about treatment are reported.Methods: I‐WISh is a cross‐sectional survey of 1507 ITP pts and 472 MDs across 13 countries; pts were recruited via MDs and pt support groups. The survey captured demographics, signs and symptoms, impact of symptoms, and pt–MD relationships. An expert MD and pt advocacy ITP specialist steering committee designed and endorsed the survey materials.Results: MDs mean no. of current and newly diagnosed ITP pts (SD) in the past year were 34 (50) and 18 (36), respectively. Pts were provided with a list of treatments and selected all that applied to them. Amongst treatments pts received at any time, CSs (79%) were the most common, followed by intravenous immunoglobulin (IVIg; 48%), other immunosuppressants (ISs; 15%), Rho[D] immune globulin (anti‐D; 13%), and cyclosporine (10%). TPO‐RAs and anti‐CD20 were used overall in 30% and 26% of pts, respectively. More pts used a TPO‐RA (17%) compared with anti‐CD20 (5%), whilst 26% of pts used CSs at the time of survey. MDs were more likely to prescribe CSs over TPO‐RAs across the platelet level 3/μL and 1st and 2nd relapses. TPO‐RAs and anti‐CD20 s were most likely to be prescribed after a 2nd (57% vs 52%) or 3rd relapse (60% vs 48%) (Fig). In choosing treatments, MDs and pts prioritized the ability to offer sustained remission (82% vs 90%), reduction in bleeding risk (86% vs 87%), fewer side effects (76% vs 86%), and avoidance of immunosuppression (61% vs 72%). TPO‐RAs were preferred by 32% of MDs for achieving sustained remission compared with splenectomy (26%), CSs (24%), anti‐CD20 (12%), or IVIg (6%). MDs estimated treatment success by achieving lasting remission occurred in 50% of TPO‐RA pts, and in 52% and 48% of splenectomy and CS pts, respectively. This was 42% and 32% in anti‐CD20 s and IVIg pts respectively. Pts rated their agreement with statements regarding the effectiveness of their current treatment on a 7‐point Likert scale where 7 = strongly agree. Scores ≥5 were banded to indicate agreement with the statement; 84% of pts on a TPO‐RA indicating they agreed that TPO‐RAs were effective at preventing bleeding. This was lower for anti‐CD20 and CSs pts (74% and 66% respectively). Most pts felt their current treatment was effective in treating ITP symptoms (TPO‐RA 78%; anti‐CD20 83%; CSs 63%; IVIg 70%). Beyond bleeding, symptoms reported by pts taking medication included fatigue (50%), anxiety surrounding unstable platelet count (32%), bruising occurring for unknown reason (30%). Immunosuppressive effect was a pt concern for CSs (64%), anti‐CD20 (56%), and IVIg (42%). With TPO‐RAs, 86% of pts valued prevention of immunosuppression and 5% disagreed. Overall satisfaction with control was perceived by 76% of pts on TPO‐RAs, 78% on anti‐CD20, 69% on IVIg, and 52% on CSs pts. 38% of pts agreed on overall satisfaction with splenectomy.Summary/Conclusion: Pts perceived TPO‐RAs and anti‐CD20 s to be similarly effective in treating ITP symptoms, with high overall satisfaction, whereas satisfaction with splenectomy was lower. ISs were used infrequently. CSs were the most common treatment pts used since diagnosis. image

  • Open Access

    UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN

    by Claire Harrison, Jonathan Mathias, Maz Campbell‐Drew, Adam J. Mead, Zack Pemberton‐Whiteley, Sahra Ali, Frances Wadelin, Gavin Taylor‐Stokes, John Waller, Barbara Taylor


  • Open Access

    Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS study

    by D. Mitra, G. Taylor-Stokes, J. Waller, K. Gibson, G. Milligan, S. Iyer

    Background: Following the approval of palbociclib as the first CDK4/6 inhibitor for HR+/HER2- advanced/metastatic breast cancer (ABC/ MBC), a need exists to understand treatment patterns associated with palbociclib combination therapies in real world clinical settings. The Ibrance Real World Insights (IRIS) study aims to address this evidence gap.


  • Open Access

    Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany

    by Emma Sullivan, James Piercy, John Waller, Christopher M Black, Sumesh Kachroo

    This study examined gastroenterologists’ motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars. Data were taken from the Adelphi Real World Biosimilars Programme, a real-world, cross-sectional study undertaken in 2015–2016 with German gastroenterologists and patients with ulcerative colitis or Crohn’s disease. Gastroenterologists provided data on their prescribing behaviour and attitudes towards biosimilars, and invited the next eight eligible consecutive consulting patients to complete a detailed questionnaire. For analysis, gastroenterologists were split into ‘Investigative’, ‘Conservative’, and ‘Other’ groups. Overall, 25 gastroenterologists and 136 patients participated. Biosimilars accounted for 80% of gastroenterologists would prescribe a bio-originator rather than biosimilar as 1st line therapy if unrestricted. Patients showed some reluctance to accept biosimilars, although of those receiving biosimilars, 79% were satisfied with the current treatment of their condition, and 69% were satisfied with the control of symptoms. Although at least 35% of patients in each analysis group reported no concerns when starting treatment with a bio-originator or biosimilar, 41% of previously biologic-naïve patients prescribed a biosimilar indicated potential side effects and potential long-term problems, and 24% not knowing enough about the drug, as concerns. Results demonstrate that there is reluctance from patients to accept biosimilars and the need to further educate patients who are unsure to allow them to be involved in decision making, highlighting the importance of patient and physician communication. There remains a need for further research into non-clinical switching and the long term impact of prescribing biosimilars.